Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Non-Small-Cell Lung 164Breast Neoplasms 111Colorectal Neoplasms 77Neoplasms 65Lung Neoplasms 61Pancreatic Neoplasms 56Stomach Neoplasms 52Neoplasm Metastasis 51Ovarian Neoplasms 45Rectal Neoplasms 43Esophageal Squamous Cell Carcinoma 38Esophageal Neoplasms 38Head and Neck Neoplasms 34Squamous Cell Carcinoma of Head and Neck 32Leukemia, Myeloid, Acute 32Recurrence 26Triple Negative Breast Neoplasms 25Small Cell Lung Carcinoma 24Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Glioblastoma 23Colonic Neoplasms 23Uterine Cervical Neoplasms 22Nasopharyngeal Carcinoma 22Lymphoma 21Lymphoma, Non-Hodgkin 20Fallopian Tube Neoplasms 20Prostatic Neoplasms 17Melanoma 17Sarcoma 16Leukemia 16

Interventions

pembrolizumab 92Gemcitabine 56Nivolumab 50Cisplatin 39atezolizumab 37Carboplatin 30avelumab 29enfortumab vedotin 26Docetaxel 23Magnetic Resonance Spectroscopy 19Mitomycin 17Ipilimumab 17Paclitaxel 16Specimen Handling 14durvalumab 11toripalimab 10sacituzumab govitecan 10Pemetrexed 10cabozantinib 9Taxes 8vinflunine 7Cyclophosphamide 7tislelizumab 6Injections 6Bevacizumab 6pemigatinib 5fludarabine 5disitamab vedotin 5Standard of Care 5Radiosurgery 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Transitional Cell × Drug Therapy × Clear all
NCT06120374 2025-12-30

Adjuvant Radioimmunotherapy Compared With Adjuvant Chemotherapy for UTUC

Peking University First Hospital

Recruiting
178 enrolled
Genitourinary

Carcinoma, Transitional Cell

NCT03410693 2022-09-28

FORT-1

Bayer

Phase 2/3 Completed
175 enrolled 19 charts
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡